NCT00643097 arm group efad6155b4e5fd622f213380378d20a9 [clinicaltrials_resource:NCT00643097/arm-group/efad6155b4e5fd622f213380378d20a9]
NCT00643097 arm group efad6155b4e5fd622f213380378d20a9 [clinicaltrials_resource:NCT00643097/arm-group/efad6155b4e5fd622f213380378d20a9]
Bio2RDF identifier
NCT00643097/arm-group/efad6155b4e5fd622f213380378d20a9
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltri ...... ad6155b4e5fd622f213380378d20a9
description [clinicaltrials_vocabulary:description]
Patients first receive 3 initi ...... dence of progression or death.
identifier
clinicaltrials_resource:NCT00643097/arm-group/efad6155b4e5fd622f213380378d20a9
title
NCT00643097 arm group efad6155b4e5fd622f213380378d20a9
@en
type
label
NCT00643097 arm group efad6155 ...... d6155b4e5fd622f213380378d20a9]
@en